106 related articles for article (PubMed ID: 27027531)
1. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.
Mori N; Imamura M; Kawakami Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Takaki S; Tsuji K; Chayama K;
Hepatol Res; 2017 Mar; 47(3):E5-E13. PubMed ID: 27027531
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H; Imamura M; Nagaoki Y; Kawakami Y; Abe H; Hayes CN; Kan H; Fukuhara T; Kobayashi T; Masaki K; Ono A; Nakahara T; Honda Y; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Hiraga N; Tsuge M; Hiramatsu A; Hyogo H; Aikata H; Takahashi S; Miki D; Ochi H; Ohishi W; Chayama K;
J Gastroenterol; 2014 Dec; 49(12):1548-56. PubMed ID: 24362944
[TBL] [Abstract][Full Text] [Related]
3. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Nagaoki Y; Imamura M; Kawakami Y; Kan H; Fujino H; Fukuhara T; Kobayashi T; Ono A; Nakahara T; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Takahashi S; Hayes CN; Ochi H; Chayama K;
Hepatol Res; 2014 Dec; 44(14):E447-54. PubMed ID: 24690180
[TBL] [Abstract][Full Text] [Related]
4. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
6. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.
Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Wakabayashi H; Ohkoshi S; Tsukishiro T; Takahashi T; Watanabe T; Terai S
World J Hepatol; 2017 Feb; 9(5):252-262. PubMed ID: 28261382
[TBL] [Abstract][Full Text] [Related]
8. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Morio R; Hatooka M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Masaki K; Ono A; Nakahara T; Urabe A; Yokoyama S; Nagaoki Y; Kawaoka T; Hiraga N; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Ochi H; Chayama K;
Hepatol Res; 2016 Nov; 46(12):1256-1263. PubMed ID: 26916827
[TBL] [Abstract][Full Text] [Related]
9. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.
Miyamura T; Kanda T; Nakamoto S; Arai M; Nakamura M; Wu S; Jiang X; Sasaki R; Haga Y; Yasui S; Ooka Y; Chiba T; Imazeki F; Mikami S; Yokosuka O
Int J Hepatol; 2014; 2014():723868. PubMed ID: 25548683
[TBL] [Abstract][Full Text] [Related]
10. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
11. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
Xie X; Zhang L; Chen YZ
Hum Immunol; 2016 Jul; 77(7):609-15. PubMed ID: 27180197
[TBL] [Abstract][Full Text] [Related]
12. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Sharafi H
J Res Med Sci; 2016; 21():72. PubMed ID: 27904617
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
14. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
[TBL] [Abstract][Full Text] [Related]
15. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
16. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Craig JC; Sharafi H
J Clin Lab Anal; 2017 Jul; 31(4):. PubMed ID: 27735085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
[TBL] [Abstract][Full Text] [Related]
18. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
19. Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis.
Wu Q; Wang C; Chen EQ; Tang H; Li ZZ; Lei XZ
Hepat Mon; 2015 Dec; 15(12):e32707. PubMed ID: 26977165
[TBL] [Abstract][Full Text] [Related]
20. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
